Global PD-1 and PD-L1 Inhibitors Market Size is valued at USD 48.7 Billion in 2024 and is predicted to reach USD 166.9 Billion by the year 2034 at a 13.2% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
PD-1 and PD-L1 Inhibitors are playing a pivotal role in cancer management treatment. PD-1 and PD-L1 Inhibitors therapy is a specialized and targeted treatment that acts via blocking the activity of PD-1 and PD-L1 immune checkpoint proteins from the surface of cells. PD-1 and PD-L1 Inhibitors have accounted for proven effectiveness and satisfactory results in the treatment of cancer. Increasing cases for cancer patients across the globe and rising focus on specific & effective cancer management treatments are propelling the demand for oncology drugs and boosting the market for global PD-1 and PD-L1 Inhibitors market. Increasing emphasis on effective cancer treatment and rising economic burden due to cancer treatment procedures has led pharmaceutical manufacturers to invest significantly in research and development activities to fulfill the existing and latent demand for oncology drugs.
The Global PD-1 and PD-L1 Inhibitors market is categorized on the basis of drug type, disease type, and region. On the basis of drug type, the market is segmented into Atezolizumab, Avelumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab, Sintilimab, and Others (Pipeline). On the basis of Indication Type, the market is segmented into Colorectal Cancer, Hodgkins Lymphoma, Melanoma, Merkel Cell Carcinoma, Non-Small-Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma, Urothelial Bladder Cancer, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among all, North America is expected to dominate the market during the analysis of forecast period.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 48.7 Billion |
| Revenue Forecast In 2034 | USD 166.9 Billion |
| Growth Rate CAGR | CAGR of 13.2% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Drug Type, By Disease Type |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Merck Co., Bristol-Myers Squibb, Roche, AstraZeneca, Pfizer, Jiangsu HengRui Medicine, Regeneron Pharmaceuticals, ONO PHARMACEUTICAL CO., LTD., Eli Lilly and Company, Innovent Biologics, Inc., BeiGene, Junshi Biosciences Co., Biocad, 4D pharma plc., Agenus Inc., Calithera., Curis, Inc., Constellation Pharmaceuticals, Inc., Compass Therapeutics, Corvus Pharmaceuticals, CytomX Therapeutics, Inc., eFFECTOR Therapeutics, Inc., Jounce Therapeutics, Inc., MacroGenics, Inc., Mirati Therapeutics, Inc. , Moderna, Inc., MultiVir, Inc., NovoCure Ltd., NeoImmuneTech, Inc., Syndax Pharmaceuticals, PrimeVax Immuno-Oncology Inc., Incyte Corporation, Trillium Therapeutics Inc., and others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global PD-1 and PD-L1 Inhibitors Market Based on Drug type
Global PD-1 and PD-L1 Inhibitors Market Based on Disease Type
Global PD-1 and PD-L1 Inhibitors Market Based on Region
Europe PD-1 and PD-L1 Inhibitors Market by Country
North America PD-1 and PD-L1 Inhibitors Market by Country
Asia Pacific PD-1 and PD-L1 Inhibitors Market by Country
Latin America PD-1 and PD-L1 Inhibitors Market by Country
Middle East & Africa PD-1 and PD-L1 Inhibitors Market by Country
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PD-1 and PD-L1 Inhibitors Market Snapshot
Chapter 4. Global PD-1 and PD-L1 Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Clinical Trial/Pipeline Analysis
4.7. Industry Analysis – Porter’s Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Key Trends in the Market
Chapter 5. Market Segmentation 1: Drugs Estimates & Trend Analysis
5.1. Drugs Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drugs:
5.2.1. Pembrolizumab
5.2.2. Nivolumab
5.2.3. Atezolizumab
5.2.4. Durvalumab
5.2.5. Avelumab
5.2.6. Cemiplimab
5.2.7. Sintilimab
5.2.8. Others
Chapter 6. PD-1 and PD-L1 Inhibitors Market Segmentation 2: Indication Estimates & Trend Analysis
6.1. Indication Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Melanoma
6.2.2. NSCLC
6.2.3. Renal cell carcinoma
6.2.4. Urothelial bladder cancer
6.2.5. Hodgkins Lymphoma
6.2.6. Merkel cell carcinoma
6.2.7. Colorectal cancer
6.2.8. Others
Chapter 7. PD-1 and PD-L1 Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Drugs, 2021-2034
7.1.2. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Indication, 2021-2034
7.1.3. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034
7.2.2. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034
7.2.3. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034
7.3.2. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034
7.3.3. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034
7.4.2. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034
7.4.3. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. MEA
7.5.1. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drug, 2021-2034
7.5.2. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by country, 2021-2034
7.5.2.1. South Africa
7.5.2.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major M &A /Research Institutes Partnerships, Alliances, and Agreements
8.2. Funding Activities
8.3. Company Profiles
8.3.1. Merck Co.
8.3.2. Bristol-Myers Squibb
8.3.3. Roche
8.3.4. AstraZeneca
8.3.5. Pfizer
8.3.6. Jiangsu HengRui Medicine
8.3.7. Regeneron Pharmaceuticals
8.3.8. ONO PHARMACEUTICAL CO., LTD.
8.3.9. Eli Lilly and Company
8.3.10. Innovent Biologics, Inc.
8.3.11. BeiGene
8.3.12. Junshi Biosciences Co.
8.3.13. Biocad
8.3.14. 4D pharma plc.
8.3.15. Agenus Inc.
8.3.16. Calithera.
8.3.17. Curis, Inc.
8.3.18. Constellation Pharmaceuticals, Inc.
8.3.19. Compass Therapeutics
8.3.20. Corvus Pharmaceuticals
8.3.21. CytomX Therapeutics, Inc.
8.3.22. eFFECTOR Therapeutics, Inc.
8.3.23. Jounce Therapeutics, Inc.
8.3.24. MacroGenics, Inc.
8.3.25. Mirati Therapeutics, Inc.
8.3.26. Moderna, Inc.
8.3.27. MultiVir, Inc.
8.3.28. NovoCure Ltd.
8.3.29. NeoImmuneTech, Inc.
8.3.30. Syndax Pharmaceuticals
8.3.31. PrimeVax Immuno-Oncology Inc.
8.3.32. Incyte Corporation
8.3.33. Trillium Therapeutics Inc.